Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telacebec in Adults With Multibacillary Leprosy
NCT07918573Phase 2Not yet recruiting
- Sponsor
- Fondation Raoul Follereau
- Start
- Dec 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Telacebec in leprosy (HD) (4 arms), sponsored by Fondation Raoul Follereau. Primary endpoint: Change from baseline in viable Mycobacterium leprae load in participants' skin lesions at Day 84. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Telacebec
03
Conditions
leprosy (HD)
Beyond the preview
Go deeper on NCT07918573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918573.